Ferric carboxymaltose vs. ferrous sulfate for the treatment of anemia in advanced chronic kidney disease: an observational retrospective study and cost analysis

In non-dialysis-dependent chronic kidney disease (NDD-CKD), erythropoiesis-stimulating agents (ESAs) and iron supplementation are essential for anemia management. Ferric carboxymaltose (FCM) is a relatively novel intravenous iron formulation used in different clinical settings, although scarce data...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Cirillo, Luigi, Somma, Chiara, Allinovi, Marco, Bagalà, Alfredo, Ferro, Giuseppe, Di Marcantonio, Elio, Bellelli, Stefania, Dallari, Lorenzo Antonio, Ballo, Piercarlo, Dattolo, Pietro Claudio
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2021
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8018957/
https://ncbi.nlm.nih.gov/pubmed/33811227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-86769-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares